Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Bewersdorf, Jan Philipp  [Clear All Filters]
2024
Kewan T, Stahl M, Bewersdorf JPhilipp, Zeidan AM. Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities. Curr Hematol Malig Rep. 2024.
2023
Stahl M, Bewersdorf JPhilipp, Xie Z, Porta MGiovanni D, Komrokji R, Xu ML, Abdel-Wahab O, Taylor J, Steensma DP, Starczynowski DT, et al. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS). Blood Rev. 2023:101128.
Bewersdorf JPhilipp, Xie Z, Bejar R, Borate U, Boultwood J, Brunner AM, Buckstein R, Carraway HE, Churpek JE, Daver NG, et al. Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1 International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS). Blood Rev. 2023:101072.
2021
Bewersdorf JPhilipp, Allen C, Mirza A-S, Grimshaw AA, Giri S, Podoltsev NA, Gowda L, Cho C, Tallman MS, Zeidan AM, et al. Hypomethylating agents and FLT3 inhibitors as maintenance treatment for acute myeloid leukemia and myelodysplastic syndrome following allogeneic hematopoietic stem cell transplant - a systematic review and meta-analysis. Transplant Cell Ther. 2021.
2019
Bewersdorf JPhilipp, Stahl M, Zeidan AM. One plus one does not always equal two, especially with regard to hypomethylating agents: The question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic . Expert Rev Hematol. 2019.
2018
Liu Y, Bewersdorf JPhilipp, Stahl M, Zeidan AM. Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?. Blood Rev. 2018.